Financière de Tubize SA EPS
¿Qué es el EPS de Financière de Tubize SA?
El EPS de Financière de Tubize SA es 5.85
¿Cuál es la definición de EPS?
Las ganancias por acción (EPS) son la parte de las ganancias de una empresa asignada a cada acción en circulación de acciones ordinarias. Se ajusta para la dilución y se calcula a lo largo de doce meses.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS de compañías en Sector Health Care en EURONEXT en comparadas con Financière de Tubize SA
¿Qué hace Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Empresas con eps similar a Financière de Tubize SA
- Jost's Engineering tiene EPS de 5.84
- Blue Star tiene EPS de 5.85
- Apollo Micro systems tiene EPS de 5.85
- Cambridge Technology Enterprises tiene EPS de 5.85
- AMGEN tiene EPS de 5.85
- WEX Inc tiene EPS de 5.85
- Financière de Tubize SA tiene EPS de 5.85
- Northern Oil and Gas tiene EPS de 5.86
- Stef S.A tiene EPS de 5.86
- Westlife Development tiene EPS de 5.86
- Northern Oil and Gas tiene EPS de 5.86
- J.B. Hunt Transport Services tiene EPS de 5.86
- e Crit SA tiene EPS de 5.86